Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX

Peking University

Status: Completed

Conditions: Macular Edema

Study type: Observational

Funder types: Other

Identifiers

NCT05372562

IRB00006761-M2022205

Details and patient eligibility

About

Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT). Recurrent CME and corresponding treatments were recorded.

Full description

Patients who were diagnosed as postoperative CME after uneventful intraocular surgery and administrated with intravitreal OZURDEX injection were reviewed. All patients underwent ophthalmic examinations at the initial visit and were followed up at months 1, 2, 3 and 6 with measurement of best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT). Recurrent CME and corresponding treatments were recorded. Risk factors of recurrent CME were analyzed

Enrollment: 30 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who were diagnosed as postoperative CME after successful phacoemulsification or vitrectomy and administrated with intravitreal dexamethasone implant (OZURDEX, Allergan, Inc, California, USA) injection were reviewed.

Exclusion criteria

• patients with retinal vascular diseases, including retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, retinal artery occlusion (RAO), Coats disease, Eales disease;
• patients with macular disease before surgery, such as age-related macular degeneration (ARMD), macular choroidal neovascularization (CNV), myopic macular degeneration, macular hole (MH), epiretinal membrane(ERM);
• patients with uveitis before surgery, including anterior, intermediate, posterior and generalized uveitis;
• patients with autoimmune disease, such as ankylosing spondylitis (AS), Vogt-Koyanagi-Harada (VKH) disease, Behcet disease.

Trial design

30 participants in 2 patient groups

patients with recurrent macular edema

Description:

after intravitreal injection of OZURDEX, patients with macular edema relapse during follow-up were recruited.

patients without recurrent edema

Description:

after intravitreal injection of OZURDEX, patients without macular edema relapse during follow-up were recruited.